Maa: Etelä-Afrikka
Kieli: englanti
Lähde: South African Health Products Regulatory Authority (SAHPRA)
Ranbaxy
ADCO-AMOCLAV 375 mg (Tablets) ADCO-AMOCLAV 625 mg (Tablets) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ADCO-AMOCLAV 375 mg (Tablets) ADCO-AMOCLAV 625 mg (Tablets) COMPOSITION: ADCO-Amoclav 375 mg: Each tablet contains: Amoxicillin trihydrate equivalent to amoxicillin 250 mg and Potassium clavulanate equivalent to clavulanic acid 125 mg Butylhydroxytoluene (as antioxidant) 0,46% m/m ADCO-Amoclav 625 mg: Each tablet contains: Amoxicillin Trihydrate equivalent to amoxicillin 500 mg and Potassium clavulanate equivalent to clavulanic acid 125 mg Butylhydroxytoluene (as antioxidant) 0,46% m/m PHARMACOLOGICAL CLASSIFICATION: A 20.1.2 Penicillins PHARMACOLOGICAL ACTION: Mechanism of action: ADCO-Amoclav is a combination of amoxicillin and potassium clavulanate. The amoxicillin component of the formulation exerts a bactericidal action against many strains of Gram positive and Gram-negative organisms. The clavulanic acid component has little or no antimicrobial action. It does, however, by inactivation of susceptible beta- lactamase protect amoxicillin from degradation by beta-lactamase enzymes produced by penicillin resistant strains of organisms. Antibacterial Activity Clavulanic acid is an irreversible inhibitor of beta-lactamases produced by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris , H. influenzae, N. gonorrhoeae and B. fragilis (In-vitro activity does not necessarily imply in-vivo efficacy). Potassium clavulanate does not inactivate the chromosomally mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinetobacter species, Citrobacter species, Enterobacter, indole positive Proteus, Providencia species and Serratia marcescens. Pharma Lue koko asiakirja